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esponsibility of Xi'aAbstract An efﬁcient screening assay was developed and validated for simultaneous assessment of
compound-mediated inhibition of six major human cytochrome P450 (CYP) enzymes. This method employed
a cocktail of six probe substrates (i.e., phenacetin, amodiaquine, diclofenac, S-mephenytoin, dextromethorphan
and midazolam for CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, respectively) as well as individual prototypical
inhibitors of the six CYP enzymes in human liver microsomes under optimized incubation conditions. The
corresponding marker metabolites (i.e., acetaminophen, N-desethylamodiaquine, 4-OH-diclofenac, 4-OH-S-
mephenytoin, dextrorphan and 1-OH-midazolam) in the incubates were quantiﬁed using LC–MS/MS methods
either by an internal standard (IS) calibration curve or a simpliﬁed analyte-to-IS peak area ratio approach. The
results showed that the IC50 values determined by the cocktail approach were in good agreement with those
obtained by the individual substrate approach as well as those reported in the literature. Besides, no remarkable
difference was observed between the two quantiﬁcation approaches. In conclusion, this new cocktail assay can
be used for reliable screening of compound-mediated CYP inhibition.
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n Jiaotong University.1. Introduction
The cytochrome P450 (CYP) enzyme system is a large and diverse
super family of heme-containing enzymes that catalyze the oxidation
of a wide variety of compounds. The primary function of CYP
enzymes lies in the elimination of xenobiotics including therapeutic
drugs and environmental toxins. These CYPs may play critical roles
in the process of drug metabolism (e.g., drug clearance). Alterations
in drug metabolism caused by co-administered drugs may lead tovier B.V. All rights reserved.
Cocktail assay for assessing inhibition of P450 271metabolic drug–drug interaction (DDI). The DDI effect may be due
to either inhibition or induction of responsible CYP enzyme(s) [1–3].
In general, CYP inhibition is more common and more serious than
CYP induction.
CYP enzyme activities can be assessed via two approaches, the
individual probe substrate method and the cocktail probe substrate
method (also known as cassette or N-in-1 method). With an
increasing number of new chemical entities synthesized, quick
methods for assessing CYP-mediated DDI potential are highly
desirable. Besides, it is commonly recommended that the CYP-
mediated DDI screening should be done as early as possible, in order
to move forward projects more efﬁciently, where throughput matters
more [4,5]. For this reason, a probe-substrate cocktail approach was
ﬁrst developed for the assessment of in vivo DDI potential in the late
of discovery stage [6,7], and introduced to in vitro studies later on.
Currently, the application of cocktail strategy has gained more and
more popularity for both in vitro and in vivo DDI studies, mainly due
to its high efﬁciency. It enables the simultaneous determination of
activities of several CYP isozymes in one assay, thus saving
signiﬁcant amount of time and resources [8–13]. However, prior to
its use, a cocktail method should be well veriﬁed to clarify the
concern in terms of interactions among the probe substrates.
To cope with the probe substrate cocktail strategy, rapid analytical
methods with no or little compromise of speciﬁcity and sensitivity are
required. Nowadays, liquid chromatography–tandem mass spectro-
metry (LC–MS/MS), which is highly sensitive and selective, has
become an instrumental tool in CYP-mediated DDI assessment. Multi-
reaction monitoring (MRM) function of the MS/MS system makes it
possible to monitor multiple compounds simultaneously in a single run,
enabling concurrent analysis of multiple probe substrates and/or their
marker metabolites. Half maximal inhibitory concentration (IC50),
representing the inhibitory potency of a compound, is generated
based on fraction of activity inhibited or uninhibited, which is normally
calculated by measuring concentrations of marker metabolite(s)
using calibration curves. There is, however, a simpler way to calculate
fraction of activity inhibited or uninhibited by substituting the
concentration with analyte-to-IS peak area ratios. In this way,
throughput can be further increased, but only after it is validated.
In the present study, a 6-probe cocktail incubation (i.e., phena-
cetin, amodiaquine, diclofenac, S-mephenytoin, dextromethorphan
and midazolam for CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4,
respectively) was established for screening those compounds-
mediated CYP inhibition in early stage of drug research. The
inhibitory potency was presented with IC50 calculated by the
amount of marker metabolites qualiﬁed by fully validated, rapid,
and accurate LC–MS/MS method. The IC50 values determined by
the cocktail approach would be compared with those obtained by
the individual substrate approach.Table 1 Summary of MS/MS parameters of metabolites and IS.
Isoform Probe Metabolite P
CYP1A2 Phenacetin Acetaminophen 1
CYP2C8 Amodiaquine Desethyl-amodiaquine 3
CYP2C9 Diclofenac 4-OH-diclofenac 3
CYP2C19 S-mephenytoin 4-OH-S-mephenytoin 2
CYP2D6 Dextromethorphan Dextrophan 2
CYP3A4 Midazolam 1-OH-midazolam 3
IS Verapamil NA 4
CE: collision energy (V); CXP: collision cell exit potential (V); DP: declus2. Materials and methods
2.1. Chemicals and reagents
Phenacetin, dextromethorphan, midazolam and ketoconazole were
purchased from the National Institutes for Food and Drug Control
(Beijing, China). Amodiaquine, sulfaphenazole, nootakatone, qui-
nidine, qucertin, α-naphthoﬂavone, diclofenac and β-NADPH
were purchased from Sigma Chemical Company (Santa, USA).
Dibasic potassium phosphate and magnesium chloride hexahydrate
were purchased from SCRC (Beijing, China). Human liver
microsomes were purchased from BD (Franklin Lakes, USA).
Acetaminophen, N-desethylamodiaquine, 4-OH-diclofenac, 4-OH-
S-mephenytoin, dextrorphan and 1-OH-midazolam were pur-
chased from TRC (Toronto, Canada). Acetonitrile and formic acid
were purchased from Merck (Darmstadt, Germany). Methanol was
purchased from Tedia (Fairﬁeld, USA). MgCl2, K2HPO4 and
KH2PO4 were purchased from SCRC (Shanghai, China).2.2. Analytical method
The MS/MS system was an Applied Biosystems API-3000 mass
spectrometer with an electrospray ionization (ESI) probe (Toronto,
Canada). MS/MS signals of analytes were ﬁrst automatically
optimized for generating compound-dependent parameters such
as declustering potential, focusing potential, collision energy
and collision cell exit potential, and then manually adjusted for
obtaining other parameters such as curtain gas, nebulizer gas,
heater gas, collision gas, source voltage and temperature. For
construction of an MS/MS method simultaneously detecting six
metabolites and IS, the mutual parameters (source-dependent
parameters) were set on behalf of 4-OH-S-mephenytoin which
represented the most challenging compound for MS/MS analysis.
The optimized ion spray voltage and temperature were set at
3000 V and 400 1C. Nitrogen gas was used for the curtain gas,
nebulizer gas (gas 1), heater gas (gas 2), collision gas, which were
set at 14 psi, 12 psi, 700 mL/min, and 8 psi, respectively. Besides
these mutual parameters, the ion transitions and other detection
parameters for the analytes and IS are summarized in Table 1.
Separation was performed on a Shimadzu LC-20AD system
equipped with two binary pumps (Kyoto, Japan), and a SIL-HTA
(Shimadzu, Japan). Commonly used organic mobile phases such
as methanol/acetonitrile and modiﬁers such as formic acid/ammo-
nium acetic were tested on three columns for the optimal
chromatographic separation and sensitivity, as well as the peak
shape. A synergy Hydro-RP (2.0 mm 50 mm, 3 μm) column
(Phenomenex, Torrance, USA) was ﬁnally chosen. The mobilerecursor Product CE CXP DP FP
52.0 110.0 23 8 26 110
28.2 219.4 61 22 46 160
12.0 231.0 29 14 31 200
35.2 150.1 25 12 21 110
58.1 199.1 53 14 31 200
42.0 203.0 42 14 31 200
55.3 165.1 30 15 30 200
tering potential (V); and FP: focus potential (V).
J.-J. Wang et al.272phases chosen for this study were 0.1% (v/v) formic acid in
water designated as A, and 0.1% (v/v) formic acid in methanol
designated as B. The ﬂow rate was 0.5 mL/min. Gradient program
was as follows: mobile phase B was held at 5% for 0.80 min; a
linear gradient was run to 60% B in 1.30 min; solvent composition
was held for 0.5 min; a second linear gradient was run to 80% B in
0.7 min; solvent composition was held for 1.4 min and solvent
composition was returned to 5% B in 0.1 min for re-equilibration.
The total run time was 5.0 min. Data were collected and processed
using Analyst 1.1 data collection and integration software.
The validation of the LC–MS/MS method was based on the FDA
guidance for bioanalytical method validation [14,15]. A blank
matrix was prepared from a blank incubation system following
the same processing steps as for other incubation systems, and
assessed for any signiﬁcant interference in the chromatographic
regions of the six metabolites and the IS. The six marker metabolites
were pooled to prepare the calibrators (0.5–100 ng/mL for all six
metabolites). Area ratio of metabolite to IS was plotted against
metabolite concentration, then weighted (1/x2) linear least-square
regression was used to generate calibration curves. The ﬁtting
equation was y¼axþb, where y represents analyte-to-IS peak ratio
and x donates nominal concentration of analytes in the pooled
calibrators. The goodness of the calibration curve ﬁtting was
checked by the back-calculated concentration of the standards and
the determination coefﬁcient (r2).2.3. Microsomal incubation
The incubations were conducted in three experimental sessions:
(1) incubation conditions in terms of incubation time and micro-
somal protein concentration were tested and optimized in the ﬁrst
session, (2) DMSO effect on CYP activity was then investigated,
and (3) the CYP inhibition experiment was performed ﬁnally.
Each incubation system (200 μL) contained phosphate buffer
(100 mM, pH 7.4), MgCl2 (3 mM), NADPH (1 mM), human liver
microsomes, probe substrate(s), and a (or no) selective inhibitor.
The incubation concentrations of the probe substrates (in indivi-
dual or cocktail manner) were set around their reported Km values,
i.e., 40, 2.0, 5.0, 40, 5.0 and 2.0 μM for phenacetin, amodiaquine,
diclofenac, S-mephenytoin, dextromethorphan and midazolam,
respectively. The reactions were initiated by the ﬁnal addition of
NADPH to the incubation systems, and then conducted at 37 1C.
Following the incubations, the reactions were terminated by
adding 400 μL ice-cold acetonitrile spiked with verapamil as the
IS. The samples were allowed for protein precipitation on ice for
15 min, then vortexed shortly, and centrifuged at 3000g
for 10 min. Supernatants were transferred into 96-well plates for
LC–MS/MS analysis.2.3.1. Incubation condition optimization
Incubation conditions were optimized by incubations of the six
probe substrates in cocktail manner in human liver microsomes at
0.05, 0.1 and 0.2 mg microsomal proteins/mL for different times
(5, 10 and 20 min). The remaining substrates and formed
metabolites in the processed samples were analyzed and conditions
were chosen according to the following criteria: (1) metabolite
formation was linear with time and enzyme concentration, (2)
substrate consumption was no more than 20% of the initial
amount, and (3) all the metabolites formed could be easily detected
by LC–MS/MS methods. The microsomal concentration and theincubation time were optimized as 0.1 mg microsomal proteins/mL
and 10 min, respectively.
2.3.2. Effect of DMSO on CYP activity
To test the effect of DMSO on CYP activity, the individual-probe
incubations with different DMSO concentration levels of 0%,
0.1%, 0.5% and 1% (v/v) were conducted under the optimized
conditions. After the incubations, the formed metabolites were
analyzed and the loss of activity was calculated as the percent
decrease of metabolite formation.
2.3.3. CYP inhibition assay
The inhibitory effects of selective inhibitors on CYP activities were
investigated in both individual-probe and cocktail-probe incubation
systems. The probe substrates were co-incubated with each of the
selective inhibitors with a series of concentration levels under the
optimized conditions. The inhibitor concentrations were set sufﬁciently
covering the reported IC50 values, i.e., 0.01, 0.03, 0.10, 0.30, 1.0, and
3.0 mM for α-naphthoﬂavone, quinidine and ketoconazole; 1.0, 3.0, 10,
30, 100, and 300 mM for quercetin; and 0.10, 0.30, 1.0, 3.0, 10, and
30 mM for sulfaphenazole and nootkatone. For the control incubation,
simply no inhibitor was co-incubated with the probe substrates.
The ﬁnal DMSO concentration in the reaction systems was kept
constant and not more than 0.5%. After the incubation, the formed
metabolites in the incubates were analyzed.
2.4. Data analysis
The uninhibited fraction of the CYP activity (remaining activity
fraction) was calculated as CI/C0, where CI and C0 donate the
concentrations of generated metabolites after incubation in the
presence and absence of the inhibitors, respectively. With the area
ratios substituting the concentrations, the uninhibited fraction can
be transformed as AI/A0, where AI and A0 represent the analyte-to-
IS peak area ratios after incubation in the presence and absence of
the inhibitors, respectively.
The IC50 values of the inhibitors were determined as appro-
priate by ﬁtting a non-linear curve of uninhibited fraction versus
incubation concentration of the inhibitors, using the following
four-parameter model (Hill equation):
y¼ 1 Bottomþ TopBottom
1þ ðIC50=xÞs
 
where Top, Bottom, S, x and y donate the maximum inhibited fraction,
the minimum inhibited fraction, the slope factor, the inhibitor
concentration, and the uninhibited fraction, respectively. The para-
meters Top and Bottom were limited between 0 and 1 by the software.3. Results and discussion
3.1. Probe substrate combination
The primary purpose of this study was to develop and validate a
cocktail method for efﬁcient assessment of CYP-mediated inhibi-
tion potential. The probe substrates used for the cocktail assay
included phenacetin (CYP1A2), amodiaquine (CYP2C8), diclofe-
nac (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan
(CYP2D6), and midazolam (CYP3A4). According to an investiga-
tion on the elimination pathways of top 200 most prescribed drugs
in 2002, CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4
contributed over 95% of the overall metabolism [16]. FDA has
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enzymes, i.e., CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, while
PhRMA suggested 5 CYP enzymes, i.e., CYP1A2, 2C9, 2C19,
2D6 and 3A4, to be considered for DDI evaluation in its white
paper. In addition, CYP2C8 is referred as a P450 enzyme of
emerging importance [17]. In this regard, it would be a good idea
to develop an in vitro cocktail method covering the 6 major human
CYP enzymes for DDI screening. All the six probe substrates used
in our cocktail assay are FDA-preferred for corresponding CYPs.
To the best of our knowledge, the six-probe substrate cocktail was
reported for the ﬁrst time in this paper.
LC–MS/MS, with its high sensitivity and speciﬁcity, has
become the routine analytical method for P450-involved DDI
studies. A major purpose of this study was to develop an analytical
method coping with the cocktail incubation protocol, aiming to
keep the whole assay system in an highly efﬁcient manner.
The single LC–MS/MS method for the simultaneous determina-
tion of multiple analytes was validated in terms of speciﬁcity,Fig. 1 Chromatograms of metabolites and IS in blank matrix observ
4-hydroxydiclofenac, 4-hydroxymephenytoin, dextrophan, 1-hydroxymidaz
the same retention time in the chromatograms of marker metabolites.linearity and accuracy. Speciﬁcity was investigated with a blank
matrix prepared from the substrate/inhibitor-free incubation sys-
tem. As shown in Fig. 1, no signiﬁcant interfering peaks were
observed over the chromatographic regions of analytes. As shown
in a representative chromatograph (Fig. 2), the retention times of
acetaminophen, N-desethylamodiquine, 4-OH-diclofenac, 4-OH-
S-mephenytoin, dextrorphan, 1-OH-midazolam and verapamil (IS)
were 2.04, 2.11, 2.96, 2.30, 2.23, 2.48 and 2.39 min, respectively.
Two peaks with the retention times of 2.04 and 2.45 min were
observed in the MRM channel of acetaminophen (152.1/110.3) using
the incubation sample shown in Fig. 2. The earlier one was recognized
as acetaminophen according to the chromatograph of standard
(Fig. 3B). The retention time of the second one was identical with
the phenacetin standard (Fig. 3C), indicating that the second peak
might be generated from phenacetin. This hypothesis was veriﬁed by
checking the chromatograph of phenacetin standard using the acet-
aminophen MRM channel (Fig. 3D). Actually, such interference had
been reported previously and was presumed to be caused by substantialed in detection channels of acetaminophen, N-desethylamodiquine,
olam, and verapamil. No signiﬁcant interfere peaks were observed at
Fig. 2 Typical chromatographic proﬁling of acetaminophen, N-desethylamodiquine, 4-hydroxydiclofenac, 4-hydroxymephenytoin, dextrophan,
1-hydroxymidazolam, and verapamil; two signiﬁcant peaks were observed in the channel of acetaminophen and the peak with earlier retention time
was identiﬁed as acetaminophen (see Fig. 3).
J.-J. Wang et al.274in-source fragmentation of phenacetin in the ESI source, yielding an
ion structurally identical to acetaminophen [18,19]. Since acetamino-
phen and phenacetin were well separated, the in-source fragmentation
of phenacetin would not affect the detection of acetaminophen.
Each calibration curve was constructed by linear ﬁtting with 6
non-zero concentration points with quantiﬁcation range of 2–100,
2–100, 1–100, 2–100, 1–100 and 1–100 ng/mL for acetamino-
phen, N-desethylamodiaquine, 4-OH-diclofenac, 4-OH-S-mephe-
nytoin, dextrorphan, and 1-OH-midazolam, respectively. Good
linearity was observed. The ﬁtted equations were y¼0.0389x
0.0106 (r¼0.9943), y¼0.0079xþ0.00418 (r¼0.9943), y¼
0.0517xþ0.13 (r¼0.9805), y¼0.0197x0.00411 (r¼0.9855),
y¼0.0293xþ0.00273 (r¼0.9980) and y¼0.0781xþ0.069 (r¼
0.9977), for acetaminophen, N-desethylamodiaquine, 4-OH-diclo-
fenac, 4-OH-S-mephenytoin, dextrorphan and 1-OH-midazolam,respectively. All the calibrators had their measured values within
720%.3.2. Optimization of incubation condition
Technically, a reliable in vitro CYP inhibition study should be
conducted under a steady-state, linear condition, which means the
metabolite formation should be linearly correlated with enzyme
concentration and incubation time under the chosen incubation
conditions. Meeting this requirement allows straightforward data
interpretation. High microsomal protein concentration level may
complicate the data interpretation because of the non-speciﬁc
binding of inhibitors or substrates to the microsomal proteins.
Microsomal protein concentration has been recommended to be no
Fig. 3 Chromatograms of acetaminophen and phenacetin detected in two detection channels. (A) Chromatogram of incubation sample observed
in acetaminophen channel (152.1/110.3). Two peaks with the retention time of 2.04 min and 2.45 min were observed. (B) Chromatogram of
acetaminophen standard observed in acetaminophen detection channel with the retention time 2.04 min, indicating that the peak with earlier
retention time in A was the target. (C) Chromatogram of phenacetin standard observed in phenacetin channel. A peak was observed at the retention
time of 2.45 min. (D) Chromatogram of phenacetin standard observed in acetaminophen transmit channel (180.0/138.2). A peak was observed at
the retention time of 2.45 min, demonstrating the cross channel interference between phenacetin and acetaminophen.
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Cocktail assay for assessing inhibition of P450 275more than 1 mg/mL by FDA or no more than 0.5 mg/mL by
PhRMA. Industrial scientists [20–23] have suggested using a
microsomal protein concentration as low as feasible for in vitro
inhibition studies. Using lower microsomal protein concentration,
however, longer incubation time might be needed to generate
sufﬁcient quantities of metabolites for quantiﬁcation, thus com-
promising the assay robustness. In addition to the analytical
requirement, an appropriate condition setting should also ensure
that no signiﬁcant depletion of substrates occurs during the
incubation. PhRMA recommends the consumption of probe
substrates no more than 20%, while FDA suggests that the probe
substrate depletion is no more than 10–30%. For a probe substrate
cocktail, incubation conditions (i.e., enzyme concentration and
incubation time) may have to be chosen with some compromise
regarding probe substrate M depletion, initial-rate reaction, and
analytical requirements for all the probe substrates.
In our experiment, different microsomal protein concentration
levels (0.05, 0.1, and 0.2 mg/mL) and incubation times (5, 10 and
20 min) were evaluated. Midazolam for CYP3A4 underwent rapid
metabolism, while S-mephenytoin for CYP2C19 and phenecetin
for CYP1A2 showed substantially low turnover rates. Formation
of all the marker metabolites was linear with time (up to 20 min) at
the protein concentration of 0.1 mg/mL, and linear with protein
concentration (up to 0.2 mg/mL) with incubation time of 10 min
for midazolam and 20 min for all other probe substrates. Based on
these results, we decided to use 0.1 mg/mL of microsomal protein
concentration and incubation time of 10 min for our cocktail assay.
All other incubation conditions are described in Section 2.3.3.3.3. Effect of DMSO on CYP activity
DMSO is routinely used to solubilize drug compounds due to its
ability to solve chemicals in a broad range of physical properties.
As shown in Fig. 4, CYP2C19 and 3A4 represent the most
sensitive isoforms to DMSO with activity loss of 55.0% and
52.7% at 1% DMSO, and 44.8% and 24.4% at 0.5%. CYP1A2,
2C8 and 2C9 were not signiﬁcantly affected by DMSO up to 1%.
CYP2D6 was a mildly affected isoform compared to others, with
activity loss of 27.8% at 1% DMSO. Since 0.1% DMSO caused
no signiﬁcant reduction of all the metabolite formation, DMSO
Table 2 Summary of IC50 values of inhibitors for six human cytochrome P450 enzymes in pooled human liver microsomes.
Isoform Inhibitor IC50 calculated with SC (μM) IC50 calculated without SC (μM)
Single Cocktail Single Cocktail
CYP1A2 α-Naphthoﬂavone 0.244 0.149 0.232 0.147
CYP2C8 Quercetin 27.6 33.5 29.1 36.2
CYP2C9 Sulfaphenazole 1.16 0.719 1.35 0.742
CYP2C19 Nootkatone 6.18 6.48 7.19 6.85
CYP2D6 Qunidine 0.129 0.182 0.104 0.180
CYP3A4 Ketoconazole 0.138 0.236 0.138 0.273
Fig. 5 Semi-log graphs obtained using individual or cocktail CYP probe substrates.
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Cocktail assay for assessing inhibition of P450 277concentration of no more than 0.1% in incubates would be
preferred for our cocktail assay. The effect of DMSO on CYP
activity has also been previously reported in several papers. For
example, CYP1A2 and 2C9 were the two CYPs least affected by
DMSO [24], while CYP2C19 and CYP3A4 were the two CYPs
most sensitive to DMSO [25,26]. Our results were consistent with
the previous reports.
In a cocktail DDI assay, sometimes the use of DMSO may
cause a problem because the pooling of several probe substrates
may have to introduce more DMSO into the incubation system.
This concern may represent a limitation of the cocktail approach,
and sometimes it may be very important to make the effort to
lower DMSO concentration. The DMSO concentration in our
cocktail assay was set to be 0.5% at which the CYP activity was
reduced by 8%, 11%, 6%, 44%, 12% and 23% for CYP1A2, 2C8,
2C9, 2C19, 2D6 and 3A4, respectively.3.4. IC50 determination and comparison
IC50 values of α-naphthoﬂavone, quercetin, sulfaphenazole, noot-
katone, quinidine and ketoconazole were measured to be 0.149 vs.
0.244 mM, 33.5 vs. 27.6 mM, 0.719 vs. 1.16 mM, 6.48 vs. 6.18 mM,
0.182 vs. 0.129 mM and 0.236 vs. 0.138 mM, respectively, using
the cocktail-probe vs. single-probe approach. The IC50 values
determined by the cocktail assay were reasonably consistent with
those reported in the literature which could be found with well-
established ranges and used as solid references. α-Naphthoﬂavone
(reported IC50: 0.04–0.2 mM [27]), quinidine (reported IC50: 0.02–
0.22 mM [28]) and ketoconazole (reported IC50: 0.09–0.24 [27])
are potent inhibitors to CYP1A2, 2D6 and 3A4, respectively, and
quercetin (reported IC50: 3.1–8.47 [27]), sulfaphenazole (reported
IC50: 0.5–1.5 [28]) and nootkatone (reported Ki of 0.5 and IC50 of
9.56 [29,30]) are potent-to-mild inhibitors to CYP2C8, CYP2C9
and CYP2C19, respectively. More importantly, the IC50 values
obtained by cocktail-probe and single-probe approaches were in
good agreement. As shown in Table 2, the difference in the IC50
values was within 2 folds. These results strongly suggest that the
cocktail assay can be reasonably used as a highly efﬁcient
screening protocol for the assessment of compound-mediated
CYP inhibition potential (Fig. 5).
From an analytical perspective, good linearity and accuracy
observed from the standards represent the essential part of the
goodness of an analytical method. Therefore, utilization of
the calibration curve constructed by the calibrators at different
concentration levels is a routine way for quantiﬁcation. Normally,
IC50 is calculated by measuring concentrations of marker meta-
bolite(s) using calibration curves. However, as an effort to further
improve the analytical throughput with little inﬂuence on the ﬁnal
results, we also investigated the shifts of IC50 values after taking
off the calibration curves from the analytical regimen. As
described in Section 2.4, IC50 was calculated by substituting the
concentration with analyte-to-IS peak area ratios. As shown in
Table 2, no remarkable difference (within 1.2-fold) was made by
doing so, which meant we could further cut the workload in the
bioanalytical process with little compromise in data quality.
The higher-throughput assay system for simultaneous evalua-
tion of six major CYP enzymes validated in this study can be used
for screening purpose based on IC50 measurement, or at a rougher
level (for example, putative inhibitor is set at only two concentra-
tion levels and IC50 is not the end-point). However, caution should
always be taken when results obtained from the cocktail methodare used to make a decisive conclusion. The value of the cocktail
methods lies in their cost/time-effectiveness with somewhat loss of
reality. A sound strategy might be a combination of a screening
step using cocktail incubation method and a sequential step using
individual probe substrates where possible inhibitory DDI would
be evaluated more accurately. This strategy has been utilized in
our laboratory as a standard procedure for assessing compound-
mediated inhibition potential and/or potency.4. Conclusion
In this work, we developed a method for higher-throughput
screening of compound-mediated inhibition of six major human
CYP enzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4) by
employing six speciﬁc substrates and LC–MS/MS. The in vitro
enzymatic reaction system was well optimized, including enzyme
concentration, reaction time as well as the effect of DMSO. The
amount of marker metabolites was qualiﬁed by a precise, sensitive
and accurate LC–MS/MS method. The IC50 values of selective
CYP inhibitors determined using the substrate cocktail were in
good agreement with those obtained with individual substrates and
with previously reported values in the literature, strongly suggest-
ing that the cocktail approach can be reasonably used as a higher-
throughput screening tool for the assessment of compound-
mediated CYP inhibition potential. Besides, no remarkable differ-
ence was observed between the IC50 obtained by standard
quantiﬁcation with calibration curves and a simpliﬁed analytical
approach with only analyte-to-IS peak area ratios, indicating that
we may use the simpliﬁed analytical approach in our cocktail
assay to further improve the throughput.
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